<DOC>
	<DOCNO>NCT02972671</DOCNO>
	<brief_summary>To compare MT005 ( MiStent ) XIENCE respect target lesion failure ( TLF ) 12 month non-inferiority trial `` real world '' patient population confirm domestic extrapolation DESSOLVE III study result valid .</brief_summary>
	<brief_title>Trial MiStent Compared Xience Japan</brief_title>
	<detailed_description>This prospective , randomize , 1:1 balance , control , double-blind , multi-center study compare clinical outcome 12 month MT005 ( MiStent ) XIENCE all-comers population , include patient symptomatic coronary artery disease include patient chronic stable angina , silent ischemia , acute coronary syndrome , qualify percutaneous coronary intervention .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Male female patient â‰¥20 year ; Patients eligible percutaneous coronary intervention ( PCI ) ; The vessel reference vessel diameter range 2.5 mm 3.75 mm . All lesion patient must comply angiographic inclusion criterion 4 stent per patient implant . The patient judge capable provide voluntary informed consent fully inform nature study , willing comply study requirement provide write informed consent approve Ethics Committee respective clinical site . Known pregnancy breastfeed time randomization plan pregnancy 12 month index treatment . Women childbearing potential must negative pregnancy test within 7 day randomization ; Known contraindication hypersensitivity sirolimus , everolimus , cobaltchromium , medication aspirin , heparin , bivalirudin , follow three medication : clopidogrel bisulfate , ticlopidine , prasugrel ; Concurrent medical condition life expectancy le 12 month ; The patient unwilling/not able return outpatient clinic 1 , 6 12 month followup ; Currently participate another trial yet primary endpoint ;</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>MiStent</keyword>
</DOC>